Edwards Lifesciences Corporation (EW)

Over the past six months, Edwards Lifesciences' stock experienced several notable events. As of February 6, 2026, the closing stock price was $78.71. Q3 2025 results showed net sales increasing by 14.7% year-over-year, but shares plunged 1.2% after the announcement. Edwards Lifesciences has gained 13.1% over the past 52 weeks, underperforming the S&P 500 Index. The FTC blocked Edwards' proposed acquisition of JenaValve due to antitrust concerns. Analysts are moderately optimistic about EW's stock, with a "Moderate Buy" rating. The company's TAVR business reaccelerated, and the TMTT segment is projected to double its revenue share by 2030.

The demand for Edwards Lifesciences' products is more influenced by clinical advancements, regulatory approvals, and the adoption of new therapies rather than traditional seasonal patterns. The expansion of TAVR indication to lower-risk patients significantly grows the addressable market. The company's Patient Engagement team also monitors emerging trends in patient needs.

Edwards Lifesciences Corporation is a medical technology company specializing in patient-focused innovations for heart disease and critical care monitoring. The company's major products include Transcatheter Aortic Valve Replacement (TAVR) systems, Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart valves, and Critical Care hemodynamic monitoring systems. Edwards Lifesciences holds a dominant global market share in TAVR.

Edwards Lifesciences operates globally through a direct sales force and independent distributors. Its primary geographical segments include the United States, Europe, Japan, and the Rest of World. Manufacturing facilities are located in Irvine, Draper, Costa Rica, the Dominican Republic, Puerto Rico, Singapore, and Limerick, Ireland.

Edwards Lifesciences maintains a strong brand reputation as a global leader in structural heart innovation, driven by a patient-focused culture. The company consistently invests in research and development. Edwards Lifesciences has been recognized on several Forbes lists. The FTC's preliminary injunction blocking its proposed acquisition of JenaValve has affected the company's reputation.

Edwards Lifesciences Corporation is largely controlled by institutional shareholders, who own 84% of the company. The Vanguard Group, Inc. and BlackRock, Inc. are major institutional owners. Individual ownership accounts for 15.02% of the company, while insiders own 1.24%. Michael A. Mussallem is the largest individual shareholder.